MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, G. H.
Right arrow Articles by Philipson, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, G. H.
Right arrow Articles by Philipson, L. H.

kappa-Opioid receptor activates an inwardly rectifying K+ channel by a G protein-linked mechanism: coexpression in Xenopus oocytes

GH Ma, RJ Miller, A Kuznetsov and LH Philipson

Department of Pharmacology, University of Chicago, Illinois 60637, USA.

cRNAs encoding the kappa-opioid receptor and an inwardly rectifying, G protein-coupled, K+ channel were coinjected into Xenopus oocytes. The effects of kappa-opioid receptor agonists and antagonists on the membrane currents in these oocytes were studied using the two-electrode voltage-clamp technique. The kappa-opioid receptor agonists U69593 and dynorphin A induced a concentration-dependent inward current (EC50 of approximately 0.3 microM and approximately 30 nM, respectively) after coinjection of both cRNAs, whereas the mu-opioid receptor agonist [D- Ala2,N-MePhe4,Gly5-ol]enkephalin (10 microM) and the delta-opioid receptor agonist [D-Pen2,5]enkephalin (1 microM) had no effect. The agonist-induced inward current was reversible upon washing out of the agonists and was inhibited in the presence of the K+ channel blocker Ba2+ (0.1 mM). The specific kappa-opioid receptor antagonist norbinaltorphimine (0.1 microM) and the nonspecific opioid receptor antagonist naloxone (1 microM) abolished the agonist-induced currents. Furthermore, the agonist-induced currents exhibited rapid desensitization in the continuous presence of the agonists or after repeated application. Preincubation of the coinjected oocytes with pertussis toxin (400 ng/ml for 3 days of 1.5 microgram/ml for 24 hr) abolished most of the agonist-induced activation of the inwardly rectifying K+ current. We therefore conclude that specific stimulation of the kappa-opioid receptor can activate the inwardly rectifying K+ channel through a pertussis toxin-sensitive G protein.

Volume 47, Issue 5, pp. 1035-1040, 05/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D. A. Jacobson, J. Cho, L. R. Landa Jr., N. A. Tamarina, M. W. Roe, J. D. Buxbaum, and L. H. Philipson
Downstream regulatory element antagonistic modulator regulates islet prodynorphin expression
Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E587 - E595.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
J. T. Williams, M. J. Christie, and O. Manzoni
Cellular and Synaptic Adaptations Mediating Opioid Dependence
Physiol Rev, January 1, 2001; 81(1): 299 - 343.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
E. T. Piros, R. C. Charles, L. Song, C. J. Evans, and T. G. Hales
Cloned delta -Opioid Receptors in GH3 Cells Inhibit Spontaneous Ca2+ Oscillations and Prolactin Release Through KIR Channel Activation
J Neurophysiol, May 1, 2000; 83(5): 2691 - 2698.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
M. Filizola, L. Laakkonen, and G. H. loew
3D modeling, ligand binding and activation studies of the cloned mouse {delta}, {micro} and {kappa} opioid receptors
Protein Eng. Des. Sel., November 1, 1999; 12(11): 927 - 942.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
S. G. Madamba, P. Schweitzer, and G. R. Siggins
Dynorphin Selectively Augments the M-Current in Hippocampal CA1 Neurons by an Opiate Receptor Mechanism
J Neurophysiol, October 1, 1999; 82(4): 1768 - 1775.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. Appleyard, J. Celver, V. Pineda, A. Kovoor, G. A. Wayman, and C. Chavkin
Agonist-dependent Desensitization of the kappa Opioid Receptor by G Protein Receptor Kinase and beta -Arrestin
J. Biol. Chem., August 20, 1999; 274(34): 23802 - 23807.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. Sun, L. H. Philipson, and R. J. Miller
Regulation of K+ and Ca++ Channels by a Family of Neuropeptide Y Receptors
J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 625 - 632.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Zhu, L.-Y. Luo, J.-G. Li, C. Chen, and L.-Y. Liu-Chen
Activation of the Cloned Human Kappa Opioid Receptor by Agonists Enhances [35S]GTPgamma S Binding to Membranes: Determination of Potencies and Efficacies of Ligands
J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 676 - 684.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
Y. J. Liao, Y. N. Jan, and L. Y. Jan
Heteromultimerization of G-Protein-Gated Inwardly Rectifying K+ Channel Proteins GIRK1 and GIRK2 and Their Altered Expression in weaver Brain
J. Neurosci., November 15, 1996; 16(22): 7137 - 7150.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Lesage, E. Guillemare, M. Fink, F. Duprat, C. Heurteaux, M. Fosset, G. Romey, J. Barhanin, and M. Lazdunski
Molecular Properties of Neuronal G-protein-activated Inwardly Rectifying K[IMAGE] Channels
J. Biol. Chem., December 1, 1995; 270(48): 28660 - 28667.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics